Filing Details

Accession Number:
0001172661-25-000616
Form Type:
13G Filing
Publication Date:
2025-02-09 19:00:00
Filed By:
Deep Track Capital
Company:
Tectonic Therapeutic Inc. (NASDAQ:TECX)
Filing Date:
2025-02-10
SEC Url:
13G Filing
Ownership Summary

Please notice the below summary table is generated without human intervention and may contain errors. Please refer to the complete filing displayed below for exact figures.

Name Beneficially Owned Number of Shares Beneficially Owned Number of Aggregate Shares Percent of Class
Deep Track Capital, LP 0 1,401,938 7.60%
Deep Track Biotechnology Master Fund, Ltd. 0 1,401,938 7.60%
David Kroin 0 1,401,938 7.60%
Filing





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)






SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G




SCHEDULE 13G


 
Deep Track Capital, LP
 
Signature:/s/ David Kroin
Name/Title:David Kroin, Managing Member of the General Partner of the Investment Adviser
Date:02/10/2025
 
Deep Track Biotechnology Master Fund, Ltd.
 
Signature:/s/ David Kroin
Name/Title:David Kroin, Director
Date:02/10/2025
 
David Kroin
 
Signature:/s/ David Kroin
Name/Title:David Kroin
Date:02/10/2025
Exhibit Information

Item 4: Information with respect to the Reporting Persons' ownership of the Common Stock as of February 10, 2025, is incorporated by reference to items (5) - (9) and (11) of the cover page of the respective Reporting Person The amount beneficially owned by each Reporting Person is determined based on 18,442,154 Common Stock outstanding. Such amount is calculated based on the 14,752,689 Common Stock outstanding according to the 10-Q filed with the SEC on November 12, 2024 and 3,689,465 Common Stock sold according to the 8-K filed with the SEC on February 3, 2025. JOINT FILING STATEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on SCHEDULE 13G, is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on SCHEDULE 13G, shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the completeness and accuracy of the information concerning him or it contained therein, but shall not be responsible for the completeness and accuracy of the information concerning the others, except to the extent that he or it knows or has reason to believe that such information is inaccurate. Dated: February 10, 2025 Deep Track Capital, LP By: /s/ David Kroin David Kroin, Managing Member of the General Partner of the Investment Adviser Deep Track Biotechnology Master Fund, Ltd. By: /s/ David Kroin David Kroin, Director David Kroin By: /s/ David Kroin David Kroin